Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6620817 | 0.88 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL5493145 | 0.87 | HDAC1 (0.46) | DRD3DRD4DRD2SIGMAR1HDAC1 | |
| SCHEMBL5498350 | 0.87 | DRD4 (0.46) | DRD3DRD4DRD2SIGMAR1HDAC1 | |
| SCHEMBL10511598 | 0.84 | DRD3 (0.46) | DRD3DRD4DRD2SIGMAR1HDAC1 | |
| SCHEMBL5495641 | 0.81 | MCHR1 (0.46) | — | |
| SCHEMBL5495222 | 0.79 | SIGMAR1 (0.42) | DRD3DRD4DRD2SIGMAR1HDAC1 | |
| SCHEMBL3043200 | 0.78 | CHRNB2 (0.52) | DRD3DRD4DRD2HDAC1 | |
| SCHEMBL24680998 | 0.78 | DRD3 (0.58) | DRD3DRD4DRD2AKR1C3HDAC1 | |
| SCHEMBL29914505 | 0.78 | DRD3 (0.58) | DRD3DRD4DRD2AKR1C3HDAC1 | |
| SCHEMBL24680997 | 0.78 | DRD3 (0.58) | DRD3DRD4DRD2AKR1C3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757608-A1 | New benzazepine derivatives, medicaments containing the same and their use in the preparation of medicaments | Sanochemia Pharmazeutika Aktiengesellschaft (AT) | 2007-02-28 | — | — | EP | disclosed |
| US-7101890-B2 | Benzazepine derivatives, drugs containing these and use of the same for producing drugs | SANOCHEMIA LTD. (MT) | 2006-09-05 | — | — | US | disclosed |
| US-20040067974-A1 | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | SANOCHEMIA LTD. (MT) | 2004-04-08 | — | — | US | disclosed |
| US-6638925-B2 | In particular benzofuro(3a,3,2,ef)(2)benzazepin; treatment of Alzheimer's disease and related dementia conditions, Langdon-Down syndrome | SANOCHEMIA LTD. (MT) | 2003-10-28 | — | — | US | disclosed |
| US-20030092700-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS | SANOCHEMIA LTD. (MT) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092700-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS | PSEN2, BACE2, BACE1 | DRD3 232/4885DRD4 945/4885DRD2 668/4885 |
| US-20040067974-A1 | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | BACE2, PSEN2, BACE1 | DRD3 241/4885DRD4 670/4885DRD2 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.